MiMedx Group Inc (MDXG)

8.39
0.38 4.30
NASDAQ : Health Care
Prev Close 8.77
Open 8.73
Day Low/High 8.36 / 8.80
52 Wk Low/High 6.64 / 12.83
Volume 318.33K
Avg Volume 743.70K
Exchange NASDAQ
Shares Outstanding 109.51M
Market Cap 960.44M
EPS 0.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Interesting MDXG Put And Call Options For February 2017

Interesting MDXG Put And Call Options For February 2017

Investors in MiMedx Group Inc saw new options begin trading this week, for the February 2017 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MDXG options chain for the new February 2017 contracts and identified one put and one call contract of particular interest.

MiMedx Comments On Meritless Lawsuit

MiMedx Comments On Meritless Lawsuit

MiMedx Applauds Passage Of 21st Century Cures Act

MiMedx Applauds Passage Of 21st Century Cures Act

Congress puts patients first in passing this groundbreaking legislation

MiMedx Announces USP-NF Monograph For DHACM Allografts Has Published

MiMedx Announces USP-NF Monograph For DHACM Allografts Has Published

MIMEDX'S PURION PROCESSED dHACM ALLOGRAFTS REPRESENT YEARS OF SCIENTIFIC RIGOR THAT CONFORM TO THE NEW USP-NF MONOGRAPH

Notable Two Hundred Day Moving Average Cross - MDXG

Notable Two Hundred Day Moving Average Cross - MDXG

In trading on Thursday, shares of MiMedx Group Inc crossed below their 200 day moving average of $8.03, changing hands as low as $7.87 per share. MiMedx Group Inc shares are currently trading down about 5.9% on the day.

MiMedx Is Grand Sponsor Of Desert Foot 2016

MiMedx Is Grand Sponsor Of Desert Foot 2016

MiMedx EpiFix®, AmnioFix®, AmnioFill™ and EpiCord™ Showcased for Wound Healing and Surgical Procedures

MiMedx Third Quarter 2016 Revenue Exceeds Upper End Of Guidance

MiMedx Third Quarter 2016 Revenue Exceeds Upper End Of Guidance

$64.4 Million Q3 2016 Revenue is 31% Increase Over Q3 2015

Advances In Regenerative Medicine With MiMedx EpiFix® And AmnioFix® To Be Presented At SAWC Fall Meeting

Advances In Regenerative Medicine With MiMedx EpiFix® And AmnioFix® To Be Presented At SAWC Fall Meeting

Presentation of Application Techniques and Therapeutic Approaches Using MiMedx EpiFix and AmnioFix for Wound Healing and Surgical Procedures

MiMedx Urges FDA To Reconsider Draft Guidances During Hearing

MiMedx Urges FDA To Reconsider Draft Guidances During Hearing

PRESENTERS OVERWHELMINGLY ASK FDA TO WITHDRAW OR SIGNIFICANTLY MODIFY DRAFT GUIDANCE

Scientific Study Confirms How MiMedx DHACM Allografts Effectively Promote Wound Repair

Scientific Study Confirms How MiMedx DHACM Allografts Effectively Promote Wound Repair

Study quantifies in MiMedx dHACM allografts numerous matrix components, growth factors, proteases and protease inhibitors known to play a role in wound healing

MiMedx Announces Nationwide Launch of AmnioFill™

MiMedx Announces Nationwide Launch of AmnioFill™

AMNIOFILL™ IS THE FIRST PRODUCT IN THE MIMEDX PLACENTAL COLLAGEN MATRIX FAMILY TO BE COMMERCIALLY INTRODUCED

MiMedx Provides Update On Key Clinical Trials

MiMedx Provides Update On Key Clinical Trials

FDA AGREES TO SHORTEN IMMUNOGENIC TESTING BY ONE YEAR IN THE COMPANY'S PLANTAR FASCIITIS STUDY

MiMedx Group (MDXG) Weak On High Volume

MiMedx Group (MDXG) Weak On High Volume

Trade-Ideas LLC identified MiMedx Group (MDXG) as a weak on high relative volume candidate